Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 67Carcinoma, Non-Small-Cell Lung 45Lung Neoplasms 42Lymphoma 36Prostatic Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Ovarian Neoplasms 27Uterine Cervical Neoplasms 23Central Nervous System Neoplasms 22Neoplasm Metastasis 21Fallopian Tube Neoplasms 21Colorectal Neoplasms 21Leukemia 20Neuroblastoma 17Head and Neck Neoplasms 17Rectal Neoplasms 16Brain Neoplasms 16Adenocarcinoma of Lung 16Sarcoma 15Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Colonic Neoplasms 14Burkitt Lymphoma 14Leukemia, Myeloid, Acute 13HIV Infections 13Urinary Bladder Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Multiple Myeloma 11Hodgkin Disease 11Astrocytoma 11

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Has results × Recurrent Uterine Corpus Carcinoma × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

NCT00006903 2019-03-20

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

GOG Foundation

Phase 2 Unknown
67 enrolled 9 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡